BioCryst Pharmaceuticals: Bank of America Sees Approximately 130% Price Potential!
Reading Time: 3 minutes
BioCryst Pharmaceuticals (BCRX) is a biotechnology company that utilizes its expertise in structure-based drug design to develop innovative oral small molecules and protein therapeutics for the treatment of hard-to-treat diseases. BioCryst has launched ORLADEYO (Berotralstat), the first oral, once-daily plasma kallikrein inhibitor, which is a therapy for the prophylaxis of attacks of hereditary angioedema (HAE). Additionally, the company is developing a pipeline of small molecules and protein therapeutics. Quarterly Report and Completed Acquisition...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
